Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
EWNEW ORLEANS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association’s Heart Valve Initiative, a national effort to improve care and outcomes for the more than 28 million people living with heart valve disease worldwide. In the U.S. alone, valve disease contributes to more than 60,000 deaths annually, many driven by delayed diagnosis or treatment. Through this initiative, the American Heart Association is establishing valve dis
EW Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
EWNEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW). If you currently own shares of Edwards stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=29704 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlegal.com. Why Rosen La
MedtechWOMEN Announces Virginia L. Giddings as Winner of the 2025 Ferolyn Powell Award
EW(NYSE:EW) MENLO PARK, Calif.--(BUSINESS WIRE)--MedtechWOMEN today announced that Virginia Giddings, Ph.D., vice president of Exploration at Edwards Lifesciences, has been named the recipient of the 2025 Ferolyn Powell Leadership Award, honoring her extraordinary contributions to advancing healthcare innovation, mentoring the next generation of leaders, and fostering diversity in the medical technology industry. The Ferolyn Powell Award, established in 2016, recognizes a rising leader in medtech who exemp
Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase
EWIRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $500 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025. Under the terms of this ASR, Edwards will receive an initial delivery of approximately 5 million shares and the remainder at the maturity of the ASR. The final number of shares to be repurchased will be ba
Edwards Lifesciences Comments on FTC’s Action to Block Proposed Acquisition of JenaValve
EWIRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Federal Trade Commission (FTC) moved to block the company’s proposed acquisition of JenaValve Technology. Edwards disagrees with FTC’s decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (AR). The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of
Assessing Edwards Lifesciences: Insights From 6 Financial Analysts
EWEdwards Lifesciences Announced New Economic And Clinical Evidence On Severe Aortic Stenosis Presented As A Late-breaking Clinical Trial At EuroPcr 2025, Further Contributing To The Extensive Body Of Research On This Disease
EWLive On CNBC, Bill Baruch Announces Bought Edward Lifesciences
EWPiper Sandler Maintains Overweight on Edwards Lifesciences, Raises Price Target to $83
EWWhat's Driving the Market Sentiment Around Edwards Lifesciences?
EWP/E Ratio Insights for Edwards Lifesciences
EWEdwards Announces TAVR Receives FDA Approval For Patients With Asymptomatic Severe Aortic Stenosis
EWCanaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $75
EWEdwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens
EWEdwards Lifesciences raised 2025 revenue forecast after Q1 results beat EPS estimates and TMTT sales jumped 58% amid strong global demand.
Baird Maintains Neutral on Edwards Lifesciences, Raises Price Target to $75
EWPiper Sandler Upgrades Edwards Lifesciences to Overweight, Raises Price Target to $80
EWEdwards Lifesciences Sees Q2 Adj EPS $0.59-$0.65 vs $0.62 Est; Sees Sales $1.450B-$1.530B vs $1.46B Est
EWEdwards Lifesciences Affirms FY2025 Adj EPS Guidance of $2.40-$2.50 vs $2.46 Est
EWEdwards Lifesciences Q1 Adj. EPS $0.64 Beats $0.60 Estimate, Sales $1.41B Beat $1.40B Estimate
EWA Look at Edwards Lifesciences's Upcoming Earnings Report
EWIs Edwards Lifesciences Gaining or Losing Market Support?
EWEdwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System Received CE Mark
EWEdwards Lifesciences Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
EWTruist Securities Maintains Hold on Edwards Lifesciences, Lowers Price Target to $75
EWHow Is The Market Feeling About Edwards Lifesciences?
EWA Look Into Edwards Lifesciences Inc's Price Over Earnings
EWPeering Into Edwards Lifesciences's Recent Short Interest
EWBarclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $90
EWCanaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $71
EWHeart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength
EWEdwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company projects continued expansion in 2025.
RBC Capital Reiterates Outperform on Edwards Lifesciences, Maintains $85 Price Target
EWPiper Sandler Maintains Neutral on Edwards Lifesciences, Raises Price Target to $73
EWEvercore ISI Group Maintains In-Line on Edwards Lifesciences, Lowers Price Target to $73
EWMorgan Stanley Maintains Equal-Weight on Edwards Lifesciences, Raises Price Target to $75
EWCitigroup Upgrades Edwards Lifesciences to Buy, Raises Price Target to $105
EWEdwards Lifesciences Announces Launch Of SAPIEN 3 Ultra RESILIA Valve
EWWhy Jim Cramer Prefers These 2 Semiconductor Stocks
EWOn CNBC’s "Mad Money Lightning Round," Jim Cramer said SoFi Technologies, Inc. (NASDAQ: SOFI) has been getting destroyed.
